Imperial Oil Limited Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.15 (market cap $6.57B). The key difference: Imperial Oil Limited Common Stock is far larger — about 9.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IMO | IOVA | |
|---|---|---|
Market Cap | $62.22B | $6.57B |
Volume | 560,544 | 11,838,721 |
Sector | Energy | Health |
52-Week High | $138.33 | $14.82 |
52-Week Low | $83.72 | $1.81 |
Enterprise Value | $63.13B | $6.50B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 1 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →